Healthy Male Volunteers
Conditions
Brief summary
For this study, the study medicine has been specially prepared to contain radiolabeled carbon \[14C\]. \[14C\] is a naturally occurring radioactive form of the element carbon. Adding a low dose of radiation to the study medicine does not change how the medicine works but helps to see how the medicine appears in the blood, urine, and stool after it is given. This type of study is called a radiolabeled study. The purpose of this radiolabeled study is to learn how a certain amount of \[14C\] PF-07799544 is taken up into the bloodstream and removed from the body. The study is seeking participants who are: Male Ages 18 to 55 years of age confirmed to be healthy based on medical and physical tests. Weigh more than 50 kilograms (kg) and have a body mass index of 17.5 to 32 kg per meter squared. The study consists of two parts. In part one, all participants will receive one full dose of \[14C\]PF-07799544 by mouth. Part two will begin at least 14 days after the dose in part one. In part two, participants will receive one full dose of PF-07799544 by mouth and one small dose of \[14C\] PF-07799544 by intravenous (IV) infusion. IV infusion will be directly injected into the veins. To understand how the medicine is processed in the body, samples of blood, urine, feces, and vomit (if any) will be collected after each dose is given. This will help understand: How much PF-07799544 is taken up into the bloodstream when taken by mouth compared to the dose given by IV How the body removes it from the blood steam. Participants will take part in the study for about 7 weeks, including evaluation at the start and follow-up period.
Detailed description
Not Provided.
Interventions
DRUGIV [14C] PF-07799544
A single IV infusion of \[14C\] PF-07799544 will be administered at the approximate Tmax after administration of the unlabeled oral dose of PF-07248144 in Period 2.
DRUGOral [14C] PF-07799544
A single oral dose of \[14C\] PF-07799544 will be administered as an extemporaneous suspension in Period 1.
DRUGOral Unlabeled PF-07799544
A single oral dose of unlabeled PF-07799544 will be administered as extemporaneous solution in Period 2.
Sponsors
Pfizer
Study design
Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
NONE
Masking description
None (Open-Label)
Intervention model description
Crossover Assignment
Eligibility
Sex/Gender
MALE
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
Males 18 to 55years of age, inclusive, at screening who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs, and 12-lead ECGs. BMI of 17.5-32 kg/m2; and a total body weight \>50 kg (110 lb).
Exclusion criteria
Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing. Previous administration of an investigational product (drug or vaccine) within 30 days or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer). Participation in studies of other investigational products (drug or vaccine) at any time during participation in this study. Total 14C radioactivity measured in plasma should not exceed 2.5 × standard biological carbon ratio.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Total recovery (%) of radioactivity in urine, feces and vomitus (if any), expressed as a percent of total oral radioactive dose administered. | Period 1 pre-dose to maximum days 15 | To characterize the extent of excretion of total radioactivity in urine, feces and vomitus (if any) following administration of a single oral dose of \[14C\]PF-07799544. |
| Metabolic profiling/identification and determination of relative abundance of [14C]PF-07799544 and the metabolites of PF-07799544 in plasma, urine and feces, if possible. | Period 1 pre-dose to maximum days 15 | To characterize the metabolic profile and identify the circulating and excreted metabolites of PF- 07799544 following administration of a single oral dose of \[14C\]PF-07799544. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The ratio of dose-normalized AUCinf (if data permit, otherwise AUClast) of oral PF-07799544 to IV [14C]PF-07799544. | Period 2 pre-dose to maximum days 6. | To determine the oral absolute bioavailability (F) of PF-07799544 from a single oral dose of PF-07799544 compared to a single IV microtracer of \[14C\]PF-07799544. |
| The ratio of total recovered radioactivity 14C in urine following single dose administration of [14C]PF-07799544 orally in Period 1 and IV microtracer, microdose administration of [14C]PF-07799544 in Period 2. | Period 1 pre-dose to maximum days 15; Period 2 pre-dose to maximum days 6. | To determine the fraction of PF-07799544 dose absorbed (Fa) from a single oral dose of \[14C\]PF-07799544. |
| Number of Participants With Treatment Emergent Adverse Events. | Baseline up to 28 to 35 days post last study intervention dose. | To evaluate the safety and tolerability of PF-07799544, administered as a single oral dose of \[14C\]PF-07799544 or a single oral dose of PF-07799544 followed by administration of a single IV microdose of \[14C\]PF-07799544. |
| Number of Participants with Treatment Emergent Clinically Significant Laboratory Abnormalities. | Baseline up to 28 to 35 days post last study intervention dose. | To evaluate the safety and tolerability of PF-07799544, administered as a single oral dose of \[14C\]PF-07799544 or a single oral dose of PF-07799544 followed by administration of a single IV microdose of \[14C\]PF-07799544. |
| Number of Participants With Treatment Emergent Clinically Significant Abnormal Vital Signs. | Baseline up to 28 to 35 days post last study intervention dose. | To evaluate the safety and tolerability of PF-07799544, administered as a single oral dose of \[14C\]PF-07799544 or a single oral dose of PF-07799544 followed by administration of a single IV microdose of \[14C\]PF-07799544. |
| Number of Participants With Treatment Emergent Clinically Significant Physical Examination Abnormalities. | Baseline up to 28 to 35 days post last study intervention dose. | To evaluate the safety and tolerability of PF-07799544, administered as a single oral dose of \[14C\]PF-07799544 or a single oral dose of PF-07799544 followed by administration of a single IV microdose of \[14C\]PF-07799544. |
| Number of Participants With Treatment Emergent Clinically Significant Abnormal ECG Measurements. | Baseline up to 28 to 35 days post last study intervention dose. | To evaluate the safety and tolerability of PF-07799544, administered as a single oral dose of \[14C\]PF-07799544 or a single oral dose of PF-07799544 followed by administration of a single IV microdose of \[14C\]PF-07799544. |
Countries
United States
Contacts
STUDY_DIRECTORPfizer CT.gov Call Center
Pfizer
Outcome results
None listed